Meeting
2024 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Authors
Do-Youn Oh
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Do-Youn Oh , Iwona A. Lugowska , Daniil Stroyakovskiy , Kyung Hae Jung , Olivier Dumas , Konstantin Penkov , Arunee Dechaphunkul , Ana Oaknin , Seung Tae Kim , Naureen Starling , Busyamas Chewaskulyong , Chanchai Charonpongsuntorn , Deborah Blythe Doroshow , Sheng-Yen Hsiao , Yi-Ping Hung , Lindsey Jung , Nataliya Kuptsova-Clarkson , Flavia Michelini , Soham D. Puvvada , Funda Meric-Bernstam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04482309
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4090)
DOI
10.1200/JCO.2024.42.16_suppl.4090
Abstract #
4090
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
First Author: Piotr Jan Wysocki
Poster
2018 Gastrointestinal Cancers Symposium
Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer.
First Author: Yoriko Yamashita-Kashima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The distribution of human epidermal growth factor receptor 2 (HER2) expression and the efficacy and safety of treatments in HER2-expressing advanced or metastatic gastroesophageal cancer: A systematic literature review (SLR).
First Author: David Bing Zhen
Poster
2023 ASCO Annual Meeting
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.
First Author: Xinan Sheng